Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3181356 | Actas Dermo-Sifiliográficas | 2009 | 13 Pages |
Abstract
The introduction of highly active antiretroviral treatment (HAART) in 1996 radically changed the clinical course of human immunodeficiency virus (HIV) infection as it led to a dramatic reduction in mortality in these patients. However, these treatments have their limitations, including adverse effects, therapeutic failure, pharmacokinetic interactions, the development of resistance, and abnormal immune responses. In this article we review the current situation of cutaneous drug reactions in HIV-infected patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
M. Blanes, I. Belinchón, J. Portilla,